Medical Treatment of Hypercortisolism with Relacorilant: **Final Results of the Phase 3 GRACE Study**

Rosario Pivonello¹, Giorgio Arnaldi², Richard J. Auchus³, Corin Badiu⁴, Robert S. Busch⁵, Salvatore Cannavo⁶, Ulrich Dischinger⁷, Georgiana A. Dobri⁸, Diane Donegan⁹, Atanaska Elenkova¹⁰, Pouneh K. Fazeli¹¹, Richard A. Feelders¹², Rogelio Garcia-Centeno¹³, Aleksandra Gilis-Januszewska¹⁴, Oksana Hamidi¹⁵, Zeina C. Hannoush¹⁶, Harold J. Miller¹⁷, Aurelian Emil Ranetti¹⁸, Monica Recasens¹⁹, Martin Reincke²⁰, Sergio Rovner²¹, Roberto Salvatori²², Julie Silverstein²³, Antonio Stigliano²⁴, Massimo Terzolo²⁵, Christina Wang²⁶, Kevin C.J. Yuen²⁷, Austin L. Hand²⁸, Iulia Cristina Tudor²⁸, Katherine A. Araque²⁸, Andreas G. Moraitis²⁸, on behalf of the GRACE investigators

¹Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia, Andrologia, Andrologia, Andrologia, Ann Arbor, MI, USA ⁴"Carol Davila" University of Medicine and Pharmacy and National Institute of Endocrinology, Bucharest, Romania. ⁵ Albany Medical College: Community Endocrine Unit, University of Messina, Italy. ⁷ Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University of Messina, Italy. ⁷ Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University of Messina, Italy. ⁷ Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University Internal Medicine, Division of Endocrinology and Diabetes, University Hospital G. Martino, University Internal Medicine, Division of Endocrinology, Bucharest, Romania. ⁵ Albany Medical College: Community Endocrine Community Endocrinology, Bucharest, R of Würzburg, Würzburg, Germany. ⁸Weill Cornell Medicine, New York, NY, USA. ⁹Division of Endocrinology, Indiana University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Indiana University School of Medicine, New York, NY, USA. ⁹Division of Endocrinology, Indiana University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Indianapolis, IN, USA. ¹⁰USHATE "Acad. Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Ivan Penchev" Department of Endocrinology, Medical University School of Medicine, Ivan Pe of Medicine, Pittsburgh, PA, USA. ¹²Erasmus Medical Center, Department of Internal Medicine, Division of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland. ¹⁵University of Texas Southwestern Medical Center, Department, Madrid, Spain. ¹⁴Chair and Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland. ¹⁵University of Texas Southwestern Medical Center, Department, Madrid, Spain. ¹⁴Chair and Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland. ¹⁵University of Texas Southwestern Medical Center, Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland. ¹⁵University of Texas Southwestern Medical Center, Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland. ¹⁵University of Texas Southwestern Medical Center, Department, Department, Medical Center, Department, Dallas, TX, USA. ¹⁶Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University Emergency Hospital "Carol Davila," Bucharest, Romania. ¹⁹Endocrinology Unit, Hospital Josep Trueta de Girona, Girona, Spain. ²⁰Medical Department IV, LMU Klinikum, LMU Munich, Munich, Germany. ²¹Frontier Medical Center, El Paso, TX, USA. 22Division of Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Department of Clinical and Molecular Medicine; Division of Endocrinology, Metabolism & Lipid Research, St. Louis, MO, USA. ²⁴Endocrinology, Division of Endoc Sapienza University of Rome, Rome, Italy. ²⁵Dept. of Clinical and Biological Sciences, University of Turin, Italy. ²⁶Clinical and Translational Science Institute, The Lundquist Institute, University of Arizona College of Medicine and Creighton School of Medicine, Phoenix, Arizona, USA. ²⁸Corcept Therapeutics Incorporated, Redwood City, CA, USA.

SUMMARY & CONCLUSIONS

- Relacorilant is a selective glucocorticoid receptor (GR) modulator in development for the treatment of endogenous hypercortisolism
- GRACE was a phase 3, randomized-withdrawal (RW) study assessing the efficacy and safety of relacorilant in patients with hypercortisolism and hypertension and/ or hyperglycemia (diabetes/impaired glucose tolerance) [IGT])
- Significant improvements in hypertension, hyperglycemia, and other manifestations of cortisol excess were observed throughout the treatment with relacorilant
- Due to relacorilant's specificity for the GR and its

OPEN-LABEL RESULTS

Patient Demographics & Baseline Characteristics

Mean (SD)	Hypertension only (n=31)	Hyperglycemia only (n=50)	Hypertension & hyperglycemia (n=71)	Overall (N=152)
Age, yrs	43.5 (11.6)	54.1 (13.7)	50.9 (12.6)	50.4 (13.2)
Female, n (%)	24 (77.4)	42 (84.0)	61 (85.9)	127 (83.6)
Weight, kg	95.2 (25.5)	91.1 (21.4)	95.0 (26.6)	93.8 (24.7)
BMI, kg/m²	33.4 (7.5)	34.8 (7.9)	35.3 (9.6)	34.7 (8.6)
Waist circumference, cm	112.8 (17.4)	114.4 (14.7)	116.1 (20.4)	114.9 (18.0)
ACTH dependent, n (%)	23 (74.2)	39 (78.0)	56 (78.9)	118 (77.6)
Plasma ACTH, pg/mL	67.7 (34.0) (n=23)	74.9 (85.0) (n=39)	78.1 (69.9) (n=56)	74.9 (69.8) (n=118)
24-h UFC, μg/d 219.5 (260.5) (n=23)		164.5 (162.1) (n=39)	231.1 (353.4) (n=56)	206.8 (284.5) (n=118)
ACTH independent, n (%) 8 (25.8)		11 (22.0)	15 (21.1)	34 (22.4)
Plasma ACTHª, pg/mL	7.3 (4.8)	20.0 (26.6)	10.0 (6.2)	12.7 (16.2)

- LSM change in fasting plasma glucose (FPG) was -25.2 mg/ dL (P=0.006; n=37) for patients with IGT/DM and -30.2 mg/dL (P=0.01; n=29) for patients with DM
- LSM change in 2-h oGTT was -85.0 mg/dL (P<0.0001; n=37) for patients with IGT/DM and -88.8 mg/dL (P<0.0001; n=29) for patients with DM

RANDOMIZED WITHDRAWAL RESULTS

Primary Endpoint Met: Hypertension

Intent-to-treat

Bars represent 95% confidence intervals

population

- In the randomized-withdrawal phase, significantly more patients receiving placebo lost hypertension control than those who continued to receive relacorilant
- Odds ratio 0.17 for relacorilant vs placebo (P=0.02)

OR 0.17

Patients receiving relacorilant were 5.9× more likely to maintain 0 hypertension response

Loss of hypertension response

P-value: 0.02



P-69

unique mechanism of action, the observed efficacy was seen:

- Without cases of relacorilant-induced irregular vaginal bleeding with endometrial hypertrophy
- Without increases in cortisol concentrations and relacorilant-induced hypokalemia
- Without reported case
- Without independent

INTROD

Relacorilant: In Development Syndrome


- A selective glucocorticoid recep
 - Decreases excess cortisol Ο binding to the GR
- Highly selective: No activity at androgen receptors
 - Structurally different from
 - Avoids unwanted progeste Ο hypertrophy, vaginal bleeding)
- Unique downstream effects
 - No clinically significant impact on adrenocorticotropic hormone (ACTH) levels, resulting in no clinically significant rise in cortisol levels

METHODS

The GRACE Phase 3 Study of Relacorilant (NCT03697109)

Туроканенна	HbA1c, %	5.4 (0.5)		
ses of adrenal insufficiency tly confirmed QT prolongation	only, hypertension and hyperglycemia	updated based on database lock; analysis date 5 July 2 hypertension and hyperglycemia, and overall). ACTH, ure; OL, open-label phase; SBP, systolic blood pressur		
DUCTION	 Favorable Safety P The majority of ad No new safety sign The frequency of set 	verse events nals were ide		
t for the Treatment of Cushing	 pattern Due to relacorilant's specific the observed efficacy was se 			
eptor modulator (SGRM)	 Without case 	s of relacori		
I activity by competing with cortisol for	endometrial h	vpertrophy		
the progesterone, mineralocorticoid, or	 Without increases hypokalemia Without repo Without indo 	rted cases c		
n mifepristone	• Without inde	pendently c		
terone receptor effects (eg, endometrial eding)	Adverse events occu	urring in ≥1		


	Relacorilant	Adverse event incidence rate (%)			
Adverse event, n (%)	(n=152)	0 5% 10% 15% 20% 25% 30% 35%			
Nausea	52 (34.2)				
Edema peripheral	50 (32.9)				
Pain in extremity	43 (28.3)				
Back pain	41 (27.0)				
Fatigue	34 (22.4)				
Headache	31 (20.4)				
Arthralgia	30 (19.7)				
Diarrhea	28 (18.4)				
Skin hyperpigmentation	24 (15.8)				
Abdominal pain upper	23 (15.1)				
Constipation	23 (15.1)	Grade 1 Asymptomatic or			
Dizziness	23 (15.1)	mild; intervention not indicated			
Paresthesia	21 (13.8)	Grade 2			
Myalgia	21 (13.8)	Moderate; minimal, local or noninvasive			
Asthenia	19 (12.5)	intervention indicated			
Vomiting	19 (12.5)	Grade 3 Severe or medically			
Abdominal pain	17 (11.2)	significant but not			
Decreased appetite	17 (11.2)	immediately life threatening			
Muscular weakness	17 (11.2)				



2024. ^aMedian ACTH was <5 pg/mL (hypertension only); 9 pg/mL (hyperglycemia adrenocorticotropic hormone; BMI, body mass index; DBP, diastolic blood ure; SD, standard deviation; UFC, urinary free cortisol.

- its (AEs) were mild to moderate in severity
- dentified
- verse events was low with no dose-dependent
- ity for the GR and its unique mechanism of action,
 - orilant-induced irregular vaginal bleeding with
 - rtisol concentrations and relacorilant-induced
 - of adrenal insufficiency
- confirmed QT prolongation

:10% of patients



Patient demographics and characteristics entering randomizedwithdrawal period


Mean (SD)	Relacorilant (n=30)	Placebo (n=32)
Age, yrs	46.6 (11.0)	48.8 (14.4)
Female, n (%)	22 (73.3)	26 (81.3)
Weight, kg	93.3 (27.4)	88.6 (21.1)
BMI, kg/m ²	33.3 (7.6)	32.6 (6.5)
Waist circumference, cm	113.8 (17.7)	108.9 (17.1)
ACTH dependent, n (%)	26 (86.7)	23 (71.9)
Plasma ACTH, pg/mL 24-h UFC, μg/d	91.7 (85.7) 257.1 (449.1)	71.7 (74.7) 301.3 (287.9)
ACTH independent, n (%)	4 (13.3)	9 (28.1)
Plasma ACTH, pg/mL 24-h UFC, μg/d	5.9 (2.3) 66.9 (36.8)	10.0 (9.0) 142.2 (194.1)

ACTH, adrenocorticotropic hormone; BMI, body mass index; SD, standard deviation; UFC, urinary free cortisol.

Improvements in Blood Pressure, Glycemic Measures, and Body Composition Maintained With Relacorilant

Blood pressure: All patients with available ABPM data

Systolic blood pressure	Diastolic blood pressure	
(24 h)	(24 h)	




- Patient population
 - 18–80 years of age Ο
 - Cushing syndrome Ο
 - Hypertension, hyperglycemia (IGT or diabetes mellitus [DM]), or Ο both
- Endpoints
 - Primary: Loss of hypertension control (at visit RW12), safety Ο
 - Secondary & exploratory: Control of hyperglycemia Ο and other cortisol-related comorbidities
- Eligibility for randomization
 - Those who completed the open-label phase and met response Ο criteria at visit OL22
 - Patients with hypertension and hyperglycemia who do not meet Ο response criteria for both must meet the respective response criteria without worsening of the other comorbidity
- **Hypertension control** (in patients with hypertension) defined as:
 - $\circ \geq 5 \text{ mm Hg decrease in mean systolic blood pressure (SBP) and/$ or diastolic blood pressure (DBP), without worsening of either (by 24-h ambulatory blood pressure monitoring [ABPM])
- Hyperglycemia control defined as:
 - Patients with <u>IGT:</u>
 - 2-h oral glucose tolerance test (oGTT) glucose normalized (<140 mg/dL)
 - Patients with <u>diabetes</u> (at least one of):
 - HbA1c decrease by $\geq 0.5\%$

I		

Data updated based on database lock; analysis date 5 July 2024. TEAEs and CTCAE grade shown. AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; OL, open label; TEAE, treatment-emergent adverse event.

Rapid & Sustained Improvements in Systolic & Diastolic Blood **Pressure With Relacorilant**




ABPM, ambulatory blood pressure monitoring; BL, baseline; LSM, least-squares mean; MMRM, mixed model for repeated measures; SE, standard error. Blood pressure measured by ABPM. Error bars: SE of the mean. LSM and SE calculated using a linear MMRM. Wilcoxon rank sum test P-values for the mean change from BL shown.

Improvements in Other Symptoms of Cushing Syndrome

Significant improvements in body composition with relacorilant

러 (kg) (cm) mass by DXA (%) mass by DXA (%) (sec)



ABPM, ambulatory blood pressure monitoring; DBP, diastolic blood pressure; ns, not significant (P≥0.05); RW, randomized withdrawal: SBP. systolic blood pressure. Blood pressure measured by ABPM. Error bars: Standard deviation. Wilcoxon rank sum test P-values for the observed mean within each treatment arm shown

Glycemic measures

	Relacorilant (n=30)	Placebo (n=32)
Change from RW baseline to week RW12 in:		
AUC _{glucose} (in patients with hyperglycemia at study entry), h*mmol/L		
n	15	19
Mean (SD)	+1.1 (4.7)	+4.9 (6.1)
Wilcoxon signed rank sum P-value ^a	ns	0.0003
HbA1c (in patients with hyperglycemia at study entry), %		
n	16	19
Mean (SD)	+0.1 (0.8)	+0.3 (0.6)
Wilcoxon signed rank sum P-value ^a	ns	0.03
HbA1c (in patients with diabetes at study entry), %		
n	13	13
Mean (SD)	+0.1 (0.8)	+0.4 (0.6)
Wilcoxon signed rank sum P-value ^a	ns	0.04

AUC_{elucces}, glucose area under the curve; HbA1c, hemoglobin A1c; ns, not significant (P≥0.05); RW, randomized withdrawal. Wilcoxon rank sum test P-values for the observed mean within each treatment arm shown. Wilcoxon signed-rank test P-values within each treatment arm

- At the end of the RW phase, patients who switched to placebo experienced significant increases in AUC_{glucose} and HbA1c
- In contrast, glycemic measures were maintained in patients who continued to receive relacorilant


- 2-h oGTT glucose normalization (<140 mg/dL) or decrease by \geq 50 mg/dL, and/or
- Total daily insulin dose decrease by ≥25% and HbA1c unchanged or decreased

Acknowledgments

This study was funded by Corcept Therapeutics Incorporated. Funding for editorial, design, and production support was provided by Corcept to Woven Health Collective (New York, NY, USA).

Disclosures

RP: Consultant/advisor: Corcept Therapeutics, Crinetics, Lundbeck, Recordati; Research support: Corcept Therapeutics, Neurocrine, Recordati, Strongbridge. GA: Consultant/advisor: HRA Pharma, Recordati. RJA: Consultant/advisor: Adrenas, Corcept Therapeutics, Crinetics, Lundbeck, Neurocrine/Diurnal, Novo Nordisk, Quest, Recordati, Sparrow, Xeris; Contracted research: Corcept Therapeutics, Crinetics, Neurocrine/Diurnal, Recordati, Spruce. CB: Research support: Corcept Therapeutics, Lundbeck, Novo Nordisk; Speaker: Ipsen, Merck, Pfizer. RSB: Consultant/advisor: Corcept Therapeutics; Honoraria: Amgen, AstraZeneca, Bayer, Eli Lilly, Novo Nordisk. SC: Consultant/advisor: Amryt, Camurus, Lundbeck, Novo Nordisk, Recordati. UD: Consultant/advisor: Recordati; Research support: Novo Nordisk; Speaker: Alnylam, Merck. GAD: Consultant/advisor: Camurus, Recordati, Xeris. DD: Consultant/advisor: Camurus; Research support: Ascendis, Corcept Therapeutics; Recordati. AE: Consultant/advisor: Novartis; Research support: Crinetics. Novartis, Recordati, Xeris. **PKF:** Consultant/advisor: Amryt, Camurus, Crinetics, Quest, Regeneron, Xeris; Research support: Corcept Therapeutics, Crinetics. **RAF:** Consultant/advisor: Corcept Therapeutics, Recordati; Research support: Corcept Therapeutics, Recordati. **RGC:** Consultant/advisor: Ipsen, Novartis, Recordati; Speaker: Ipsen, Novo Nordisk, Recordati, Sanofi. AGJ: Nothing to disclose. OH: Consultant/advisor: Amryt, Corcept Therapeutics, Lantheus, Neurocrine, Recordati, Xeris. ZCH: Nothing to disclose. HJM: Nothing to disclose. AER: Nothing to disclose. MoR: Nothing to disclose. MaR: Consultant/advisor: Crinetics, HRA Pharma, Ipsen, Lundbeck; Recordati; Speaker: HRA Pharma, Recordati. SR: Speaker: Amgen, Bayer, Corcept Therapeutics, Eli Lilly, Novo Nordisk. RS: Consultant/advisor: Camurus, Chiesi, Crinetics, Lundbeck. JS: Consultant/advisor: Camurus, Corcept Therapeutics, Xeris; Research support: AbbVie, Amryt, Ascendis, Bayer, Camurus, Fractyl, Recordati, Sparrow. AS: Nothing to disclose. MT: Consultant/advisor: HRA Pharma; Research support: Corcept Therapeutics. **CW:** Nothing to disclose. **KCJY:** Consultant/advisor: Ascendis, Chiesi, Crinetics, Ipsen, Neurocrine, Novo Nordisk, Recordati, Xeris; Research support: Barrow Neurological Institute, Ascendis, Chiesi, Corcept Therapeutics, Sparrow; Speaker: Novo Nordisk, Recordati ALH, ICT, KAA, AGM: Employees: Corcept Therapeutics.



BL, baseline; DXA, dual energy X-ray absorptiometry; OL, open label; QOL, quality of life. Error bars: Standard deviation. Wilcoxin rank sum test P-values for the mean change from baseline shown.

Rapid & Sustained Improvements in Hyperglycemia With Relacorilant

- Among patients with hyperglycemia, significant least-squares mean (LSM) changes in glucose area under the curve (AUC_{glucose}) occurred from baseline to visit OL14 (-2.1 h*mmol/L; P=0.002; n=77), OL18 (-2.7 h*mmol/L; P=0.0001; n=69) and OL22 (-2.7 h*mmol/L; P=0.0002; n=69)
- Greater improvement in glucose parameters occurred with relacorilant in hyperglycemia responders from baseline to visit OL22:
 - LSM change in HbA1c was -0.7% (P<0.0001; n=37) for patients with IGT/DM and -0.9% (P<0.0001; n=29) for patients with DM

Body composition

- Similar trends observed across measures of body composition (body weight, waist circumference, tissue fat mass, tissue lean mass)
- Those who switched to placebo experienced a deterioration in body composition
- In contrast, trends toward further improvement were observed in the relacorilant arm

Favorable Safety Profile

Adverse events occurring in \geq 5% of patients

n (%)	Relacorilant (n=30)	Placebo (n=32)	RelacorilantPlacebo10.06.76.312.5Back pain
Back pain	5 (16.7)	6 (18.8)	10.0 9.4 3.1 Headache
Headache	3 (10.0)	4 (12.5)	10.0 6.3 3.1 Arthralgia
Arthralgia	3 (10.0)	3 (9.4)	6.3 6.3 Insomnia 6.3 6.3 Pain in extremity
Insomnia	0	4 (12.5)	20 10 0 10 20
Pain in extremity	2 (6.7)	2 (6.3)	Patients (%) Grade 1 Grade 2 Grade 1 Grade 2

Presented at the Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE), 10-13 May 2025, Copenhagen, Denmark